orbifloxacin has been researched along with Canine Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Odoi, A; Oguttu, JW; Qekwana, DN; Sithole, F | 1 |
| Harada, K; Kataoka, Y; Shimizu, T | 1 |
| Harada, K; Shimizu, T | 1 |
| Choi, MJ; Damte, D; Gebru, E; Kim, YH; Lee, SJ; Park, SC | 1 |
| Katz, T; Kay-Mugford, PA; Ngoh, M; Simmons, R; Varma, KJ; Weingarten, AJ; White, A; Zolynas, R | 1 |
| Etoré, F; Ganière, JP; Médaille, C | 1 |
| Miller, WH; Peters, J; Scott, DW | 1 |
7 other study(ies) available for orbifloxacin and Canine Diseases
| Article | Year |
|---|---|
Patterns and predictors of antimicrobial resistance among Staphylococcus spp. from canine clinical cases presented at a veterinary academic hospital in South Africa.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Dog Diseases; Dogs; Doxycycline; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Enrofloxacin; Female; Fluoroquinolones; Hospitals, Animal; Kanamycin; Lincomycin; Male; Retrospective Studies; South Africa; Spectinomycin; Staphylococcal Infections; Staphylococcus; Trimethoprim, Sulfamethoxazole Drug Combination; Tylosin | 2017 |
Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Escherichia coli; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus | 2013 |
Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Disease Eradication; Dog Diseases; Dogs; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2017 |
Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Base Sequence; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Enrofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation | 2012 |
Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Ciprofloxacin; Dog Diseases; Dogs; Drug Administration Schedule; Female; Male; Pyoderma; Skin; Tissue Distribution; Treatment Outcome | 2002 |
In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dog Diseases; Dogs; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Otitis Externa; Pyoderma; Staphylococcal Skin Infections; Staphylococcus | 2004 |
Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Dog Diseases; Dogs; Female; Male; Pyoderma; Staphylococcal Infections; Time Factors; Treatment Outcome | 2006 |